Q-omics provides the consensus-scored IGHV1OR16-2 profile across patient tissues and cancer cell-line models. IGHV1OR16-2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGHV1OR16-2 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, IGHV1OR16-2 RNA expression shows 5,493 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, LUAD, and HNSC as cancer lineages where IGHV1OR16-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHV1OR16-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHV1OR16-2 survival associations across molecular data types. IGHV1OR16-2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHV1OR16-2 RNA expression–survival associations across cancer types. High IGHV1OR16-2 expression shows unfavorable associations in UVM, CHOL, GBM and COAD, but favorable associations in HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGHV1OR16-2 RNA expression.
This table summarizes IGHV1OR16-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHV1OR16-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHV1OR16-2 shows lower tumor expression in COAD and READ and higher tumor expression in LUAD. The LUAD box plot shows higher IGHV1OR16-2 RNA expression in tumor versus normal tissue (log2 FC = +0.215, t-test p < 0.001).
This table shows molecular features associated with IGHV1OR16-2 in patient tissues and cancer cell lines. In patient samples, IGHV1OR16-2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
